Measles - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：58頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Measles - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Measles - Pipeline Review, H1 2014’, provides an overview of the Measles’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Measles, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Measles and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Measles
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Measles and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Measles products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Measles pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Measles
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Measles pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Measles - Pipeline Review, H1 2014’, provides an overview of the Measles’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Measles, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Measles and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Measles
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Measles and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Measles products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Measles pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Measles
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Measles pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Measles Overview 7
Therapeutics Development 8
Pipeline Products for Measles - Overview 8
Pipeline Products for Measles - Comparative Analysis 9
Measles - Therapeutics under Development by Companies 10
Measles - Therapeutics under Investigation by Universities/Institutes 12
Measles - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Measles - Products under Development by Companies 16
Measles - Products under Investigation by Universities/Institutes 17
Measles - Companies Involved in Therapeutics Development 18
Vical Incorporated 18
GlaxoSmithKline plc 19
Zydus Cadila Healthcare Limited 20
LG Life Sciences, Ltd. 21
Cadila Pharmaceuticals Ltd. 22
Beijing Tiantan Biological Products Co., Ltd. 23
VBI Vaccines 24
Serum Institute of India Limited 25
China Biologic Products, Inc. 26
Universal Stabilization Technologies, Inc. 27
Measles - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
measles, mumps and rubella vaccine (live) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GSK-208136 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Human Hepatitis B Immunoglobulin (pH4) For Intarvenous Injection - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Aerosol Measles Vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
M-Vac - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Measles and Rubella Vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Vaccine For Live Measles, Mumps and Rubella - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Measles Vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Live Measles Vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Adenovirus Vectored Vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Non-Nucleoside Inhibitors For Measles - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Vaxfectin-Formulated Measles DNA Vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
LBVP-0101 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
MMR + Varicella Vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Thermostable IM Measles Vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Measles-Rubella Vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Measles - Recent Pipeline Updates 52
Measles - Dormant Projects 53
Measles - Product Development Milestones 54
Featured News & Press Releases 54
Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Proquad 54
Aug 21, 2008: Vaxfectin Formulated Measles DNA Vaccine Could Address Unmet Need for Infants 54
Sep 06, 2005: FDA Approves ProQuad, the First and Only Vaccine in the U.S. to Help Protect Children Against Measles, Mumps, Rubella and Chickenpox in One Shot. ProQuad Combines Two Well-Established Merck Vaccines, M-M-R II and VARIVAX. 55
Nov 04, 2004: Merck Files Biologics License Application for ProQuad With U.S. Food and Drug Administration. 55
May 13, 2004: ProQuad, Merck's Investigational Combination Vaccine, Resulted in Antibody Responses Similar to Those with M-M-R IIand Varivax in New Study. 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58
List of Tables
Number of Products under Development for Measles, H1 2014 8
Number of Products under Development for Measles - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Measles - Pipeline by Vical Incorporated, H1 2014 18
Measles - Pipeline by GlaxoSmithKline plc, H1 2014 19
Measles - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 20
Measles - Pipeline by LG Life Sciences, Ltd., H1 2014 21
Measles - Pipeline by Cadila Pharmaceuticals Ltd., H1 2014 22
Measles - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2014 23
Measles - Pipeline by VBI Vaccines, H1 2014 24
Measles - Pipeline by Serum Institute of India Limited, H1 2014 25
Measles - Pipeline by China Biologic Products, Inc., H1 2014 26
Measles - Pipeline by Universal Stabilization Technologies, Inc., H1 2014 27
Assessment by Monotherapy Products, H1 2014 28
Assessment by Combination Products, H1 2014 29
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 31
Number of Products by Stage and Route of Administration, H1 2014 33
Number of Products by Stage and Molecule Type, H1 2014 35
Measles Therapeutics - Recent Pipeline Updates, H1 2014 52
Measles - Dormant Projects, H1 2014 53
List of Figures
Number of Products under Development for Measles, H1 2014 8
Number of Products under Development for Measles - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 28
Number of Products by Top 10 Route of Administration, H1 2014 32
Number of Products by Stage and Top 10 Route of Administration, H1 2014 33
Number of Products by Top 10 Molecule Type, H1 2014 34
Number of Products by Stage and Top 10 Molecule Type, H1 2014 35
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Measles Overview 7
Therapeutics Development 8
Pipeline Products for Measles - Overview 8
Pipeline Products for Measles - Comparative Analysis 9
Measles - Therapeutics under Development by Companies 10
Measles - Therapeutics under Investigation by Universities/Institutes 12
Measles - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Measles - Products under Development by Companies 16
Measles - Products under Investigation by Universities/Institutes 17
Measles - Companies Involved in Therapeutics Development 18
Vical Incorporated 18
GlaxoSmithKline plc 19
Zydus Cadila Healthcare Limited 20
LG Life Sciences, Ltd. 21
Cadila Pharmaceuticals Ltd. 22
Beijing Tiantan Biological Products Co., Ltd. 23
VBI Vaccines 24
Serum Institute of India Limited 25
China Biologic Products, Inc. 26
Universal Stabilization Technologies, Inc. 27
Measles - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
measles, mumps and rubella vaccine (live) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GSK-208136 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Human Hepatitis B Immunoglobulin (pH4) For Intarvenous Injection - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Aerosol Measles Vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
M-Vac - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Measles and Rubella Vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Vaccine For Live Measles, Mumps and Rubella - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Measles Vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Live Measles Vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Adenovirus Vectored Vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Non-Nucleoside Inhibitors For Measles - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Vaxfectin-Formulated Measles DNA Vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
LBVP-0101 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
MMR + Varicella Vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Thermostable IM Measles Vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Measles-Rubella Vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Measles - Recent Pipeline Updates 52
Measles - Dormant Projects 53
Measles - Product Development Milestones 54
Featured News & Press Releases 54
Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Proquad 54
Aug 21, 2008: Vaxfectin Formulated Measles DNA Vaccine Could Address Unmet Need for Infants 54
Sep 06, 2005: FDA Approves ProQuad, the First and Only Vaccine in the U.S. to Help Protect Children Against Measles, Mumps, Rubella and Chickenpox in One Shot. ProQuad Combines Two Well-Established Merck Vaccines, M-M-R II and VARIVAX. 55
Nov 04, 2004: Merck Files Biologics License Application for ProQuad With U.S. Food and Drug Administration. 55
May 13, 2004: ProQuad, Merck's Investigational Combination Vaccine, Resulted in Antibody Responses Similar to Those with M-M-R IIand Varivax in New Study. 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58
List of Tables
Number of Products under Development for Measles, H1 2014 8
Number of Products under Development for Measles - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Measles - Pipeline by Vical Incorporated, H1 2014 18
Measles - Pipeline by GlaxoSmithKline plc, H1 2014 19
Measles - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 20
Measles - Pipeline by LG Life Sciences, Ltd., H1 2014 21
Measles - Pipeline by Cadila Pharmaceuticals Ltd., H1 2014 22
Measles - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2014 23
Measles - Pipeline by VBI Vaccines, H1 2014 24
Measles - Pipeline by Serum Institute of India Limited, H1 2014 25
Measles - Pipeline by China Biologic Products, Inc., H1 2014 26
Measles - Pipeline by Universal Stabilization Technologies, Inc., H1 2014 27
Assessment by Monotherapy Products, H1 2014 28
Assessment by Combination Products, H1 2014 29
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 31
Number of Products by Stage and Route of Administration, H1 2014 33
Number of Products by Stage and Molecule Type, H1 2014 35
Measles Therapeutics - Recent Pipeline Updates, H1 2014 52
Measles - Dormant Projects, H1 2014 53
List of Figures
Number of Products under Development for Measles, H1 2014 8
Number of Products under Development for Measles - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 28
Number of Products by Top 10 Route of Administration, H1 2014 32
Number of Products by Stage and Top 10 Route of Administration, H1 2014 33
Number of Products by Top 10 Molecule Type, H1 2014 34
Number of Products by Stage and Top 10 Molecule Type, H1 2014 35
